Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

July 31, 2012

Study Completion Date

April 30, 2014

Conditions
Ovarian Cancer
Interventions
DRUG

Sorafenib

DRUG

Paclitaxel

Paclitaxel

DRUG

Carboplatin

Carboplatin

Trial Locations (17)

20817

Center for Cancer and Blood Disorders, Bethesda

National Capital Clinical Research Consortium, Bethesda

23601

Peninsula Cancer Center, Newport News

29210

South Carolina Oncology Associates, PA, Columbia

30912

Medical College of Georgia Cancer Specialists, Augusta

33308

Holy Cross Hospital, Fort Lauderdale

33705

Gulfcoast Oncology Associates, St. Petersburg

33901

Florida Cancer Specialists, Fort Myers

37023

Tennessee Oncology, PLLC, Nashville

37411

Tennessee Valley Clinical Research, Chattanooga

38017

Family Cancer Center, Collierville

45242

Oncology Hematology Care, Cincinnati

47802

Providence Medical Group, Terre Haute

48106

St. Joseph Mercy Hospital, Ann Arbor

49503

Grand Rapids Clinical Oncology Program, Grand Rapids

72401

Northeast Arkansas Clinic, Jonesboro

73104

University of Oklahoma, Oklahoma City

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER